We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
- Authors
Wu, Trudy C.; Lee, Alan; Suh, Robert; Oughourlian, Talia C.; Abtin, Fereidoun; Hagio, Mary Ann; Sang-June Park; Chang, Albert J.; Moghanaki, Drew
- Abstract
Patients with primary tumor progression after stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) have a second chance at complete tumor eradication with salvage local therapies, including lung resection, repeat course of SBRT, and percutaneous ablative therapies. In this paper, we presented our institution's initial experience with percutaneous high-dose-rate (HDR) brachyablation for a relapsed stage I NSCLC that had been treated with SBRT 4.3 years earlier. Lung tumor measuring approximately 5 cm in maximum tumor dimension at the time of relapse was histopathologically confirmed to be persistent squamous cell carcinoma, and successfully treated with a single fraction of 24 Gy with HDR brachyablation. Treatment was delivered via two percutaneous catheters inserted under CT-guidance, and treated in less than 20 minutes. The patient was discharged home later the same day without the need for a chest tube, and has been monitored with serial surveillance scans every 3 to 6 months without evidence of further lung cancer progression or complications at 2.8 years post-HDR brachyablation procedure and 7.8 years after initial SBRT.
- Subjects
STEREOTACTIC radiotherapy; NON-small-cell lung carcinoma; CHEST tubes; LUNG cancer; TREATMENT effectiveness
- Publication
Journal of Contemporary Brachytherapy, 2024, Vol 16, Issue 2, p150
- ISSN
1689-832X
- Publication type
Article
- DOI
10.5114/jcb.2024.139103